Welcome to our dedicated page for Radiopharm Theranostics SEC filings (Ticker: RADX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Radiopharm Theranostics Limited (RADX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Radiopharm files reports on Form 20‑F and Form 6‑K under the Securities Exchange Act of 1934, often furnishing Australian Securities Exchange announcements as exhibits for U.S. investors.
Recent Form 6‑K filings reference clinical and corporate milestones, such as interim Phase 2b data for 18F‑RAD101 in brain metastases, progress in Phase 1 trials of 177Lu‑RAD202 and 177Lu‑RAD204, ethics approval for the RAD402 prostate cancer trial, and U.S. FDA IND clearance for RV‑01 (Betabart). Other 6‑K submissions include notices of annual and extraordinary general meetings, results of shareholder votes, director interest notices, quarterly cash flow reports and presentations to investors.
Through this page, users can review how Radiopharm reports on its radiopharmaceutical pipeline, including imaging and therapeutic candidates targeting FASN, HER2, PD‑L1, αvβ6‑integrin, KLK3 and B7H3. Filings may also reference capital raisings, cash runway commentary and supply agreements for key radioisotopes used in clinical trials.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand trial updates, board and governance changes, and financing terms. Real‑time ingestion from EDGAR means new 6‑K and 20‑F submissions appear promptly, while integrated views of director interest notices and meeting results help track governance and potential insider‑related changes without manually reading every exhibit.
Radiopharm Theranostics Limited furnished a Form 6-K to share three Australian Securities Exchange announcements dated October 20, 2025. The exhibits include: “RAD completes A$35 M Placement and launches A$5 M SPP,” “RAD Provides Positive Clinical Updates Across Four Programs,” and “Investor Presentation - Clinical Update and Capital Raising.”
The company attached these items as Exhibits 99.1, 99.2, and 99.3. The submission states the materials are furnished, not filed, and are not incorporated by reference unless specifically noted.
Radiopharm Theranostics Limited filed a Form 6-K as a foreign private issuer to furnish a public notice previously released on the Australian Securities Exchange. The attached exhibit is an announcement dated October 1, 2025 titled “Radiopharm received approval for RAD 202 trial acceleration.” This means the company has received approval related to speeding up its RAD 202 trial and is sharing that information with U.S. investors. The Form 6-K states that this report, including the exhibit, is not deemed “filed” under the U.S. securities laws and will only be incorporated into other securities filings if later specifically referenced.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an announcement it released to the Australian Securities Exchange. The exhibit, titled “Radiopharm Theranostics Partners with Starpharma on Research,” indicates the company has entered into a research-focused partnership with Starpharma, though specific terms are contained in the attached announcement rather than this summary document. The company also clarifies that this Form 6-K, including its exhibit, is being furnished rather than filed under U.S. securities laws and will only be incorporated into other securities filings if specifically referenced.
Radiopharm Theranostics Limited (RDPTF) reported a challenging year ending June 30, 2025, with a total comprehensive loss of A$37.88 million and negative operating cash flows of approximately A$36.65 million. The group recorded accumulated losses of A$145.73 million and significant research and development investment, including R&D expenses of A$27.52 million (line item) and intangible assets on the balance sheet of A$49.09 million.
The company generated other income including an R&D tax incentive (A$9.37 million recognised) and raised cash from financing activities (A$45.43 million reported in one table). Key governance and management details are disclosed, including CEO Riccardo Canevari and a Board with named directors and option/share holdings. The filing also discloses material contingent consideration balances, significant finance expenses and assumptions used in impairment and contingent consideration models.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing furnishes as an exhibit a Public Notice dated September 17, 2025 titled “Corporate Governance Statement and Appendix 4G.”
The attached materials relate to the company’s corporate governance disclosures and associated compliance appendix. The Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated by reference into other Securities Act filings unless specifically referenced.
Radiopharm Theranostics Limited submitted a Form 6-K to provide U.S. investors with a copy of an announcement it lodged with the Australian Securities Exchange. The filing mainly furnishes an exhibit describing a key opinion leader webinar titled “Pivalate (Brain Mets) key opinion leader webinar.”
The document clarifies that this Form 6-K, including the attached exhibit, is furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if specifically referenced.
Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing explains that the company published an announcement to the ASX on August 29, 2025 and attaches that disclosure as an exhibit. The exhibit, labeled 99.1, is the company’s Appendix 4E and preliminary final report. The company also notes that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if specifically referenced.
Radiopharm Theranostics Limited furnished a Form 6-K to the U.S. Securities and Exchange Commission to share information previously announced on the Australian Securities Exchange. The filing attaches an announcement titled “Radiopharm to host key opinion leader webinar series” as an exhibit.
The company states that this Form 6-K and its exhibit are being furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated into other U.S. securities law filings unless specifically referenced.